WO2004082570A3 - Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) - Google Patents
Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) Download PDFInfo
- Publication number
- WO2004082570A3 WO2004082570A3 PCT/EP2004/002184 EP2004002184W WO2004082570A3 WO 2004082570 A3 WO2004082570 A3 WO 2004082570A3 EP 2004002184 W EP2004002184 W EP 2004002184W WO 2004082570 A3 WO2004082570 A3 WO 2004082570A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- drd2
- therapeutics
- diagnostics
- diseases associated
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9413—Dopamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03005469 | 2003-03-17 | ||
EP03005469.6 | 2003-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004082570A2 WO2004082570A2 (en) | 2004-09-30 |
WO2004082570A3 true WO2004082570A3 (en) | 2005-01-27 |
Family
ID=33016823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/002184 WO2004082570A2 (en) | 2003-03-17 | 2004-03-04 | Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2004082570A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017009841A (en) | 2015-01-30 | 2018-02-09 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy. |
NZ745425A (en) | 2016-01-29 | 2023-03-31 | Oncoceutics Inc | G protein-coupled receptor (gpcr) modulation by imipridones |
US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
KR102128251B1 (en) * | 2019-05-27 | 2020-06-30 | 사회복지법인 삼성생명공익재단 | Biomarker Composition for Diagnosing Colorectal Cancer Specifically Binding to Arginine-methylated Dopamine Receptor D2 |
CN115068612B (en) * | 2021-08-18 | 2023-05-23 | 四川大学华西第二医院 | Application of DRD2 inhibitor in preparation of medicines for treating liver fibrosis-related diseases |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991005040A1 (en) * | 1989-09-27 | 1991-04-18 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Cloned genes for human dopamine d2 receptors and cell lines expressing same |
WO1996034094A1 (en) * | 1995-04-26 | 1996-10-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Non-human transgenic animal with modified d2 receptor expression |
WO1999066935A1 (en) * | 1998-06-20 | 1999-12-29 | Medical Research Council | Male contraceptive comprising a prolactin inhibitor and a sex steroid |
US20010005724A1 (en) * | 1996-12-18 | 2001-06-28 | Cross Dee L. | Method for promoting ovulation, parturition, and lactation in mammals |
WO2001072741A2 (en) * | 2000-03-28 | 2001-10-04 | Knoll Gmbh | N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders |
WO2002020491A1 (en) * | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazine derivatives and their use as psychotropic agents |
US20020123096A1 (en) * | 1988-11-18 | 2002-09-05 | Oregon Health Sciences University. | Dopamine receptors and genes |
WO2003012143A1 (en) * | 2001-07-16 | 2003-02-13 | Price Foundation Limited | Genes and snps associated with eating disorders |
-
2004
- 2004-03-04 WO PCT/EP2004/002184 patent/WO2004082570A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020123096A1 (en) * | 1988-11-18 | 2002-09-05 | Oregon Health Sciences University. | Dopamine receptors and genes |
WO1991005040A1 (en) * | 1989-09-27 | 1991-04-18 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Cloned genes for human dopamine d2 receptors and cell lines expressing same |
WO1996034094A1 (en) * | 1995-04-26 | 1996-10-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Non-human transgenic animal with modified d2 receptor expression |
US20010005724A1 (en) * | 1996-12-18 | 2001-06-28 | Cross Dee L. | Method for promoting ovulation, parturition, and lactation in mammals |
WO1999066935A1 (en) * | 1998-06-20 | 1999-12-29 | Medical Research Council | Male contraceptive comprising a prolactin inhibitor and a sex steroid |
WO2001072741A2 (en) * | 2000-03-28 | 2001-10-04 | Knoll Gmbh | N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders |
WO2002020491A1 (en) * | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazine derivatives and their use as psychotropic agents |
WO2003012143A1 (en) * | 2001-07-16 | 2003-02-13 | Price Foundation Limited | Genes and snps associated with eating disorders |
Non-Patent Citations (4)
Title |
---|
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1998, BROWNELL J: "Quinagolide in hyperprolactinaemia", XP002289640, Database accession no. EMB-1998093760 * |
LAHTI R A ET AL: "DOPAMINE D-2 RECEPTOR BINDING PROPERTIES OF TRITIATED U-86170 A DOPAMINE RECEPTOR AGONIST", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 202, no. 2, 1991, pages 289 - 291, XP002289638, ISSN: 0014-2999 * |
MORO MAKOTO ET AL: "Effects of dopamine D2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemima/anovulation model in rats", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 28, no. 8, August 2001 (2001-08-01), pages 651 - 658, XP002289639, ISSN: 0305-1870 * |
REVIEWS IN CONTEMPORARY PHARMACOTHERAPY 1998 UNITED KINGDOM, vol. 9, no. 1, 1998, pages 1 - 75, ISSN: 0954-8602 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004082570A2 (en) | 2004-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003081258A3 (en) | Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs) | |
WO2004082570A3 (en) | Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) | |
WO2004042402A3 (en) | Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) | |
WO2004099782A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39) | |
WO2005074969A3 (en) | Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1) | |
WO2004081563A3 (en) | Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a) | |
WO2005093091A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) | |
WO2004099783A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4) | |
WO2004071378A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) | |
WO2004038405A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) | |
WO2004086034A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3) | |
WO2005093423A3 (en) | Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara) | |
WO2005095984A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a) | |
WO2004080374A3 (en) | Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c) | |
WO2004106935A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103) | |
WO2004086047A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) | |
WO2003066077A3 (en) | Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1) | |
WO2005040791A3 (en) | Diagnostics and therapeutics for diseases associated with somatostatin- and angiogenin-like peptide receptor (salpr) | |
WO2004038421A3 (en) | Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41) | |
WO2004073587A3 (en) | Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1) | |
WO2004099781A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1) | |
WO2005114209A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 2 (grk2) | |
WO2005040790A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75) | |
WO2003100435A3 (en) | Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2) | |
WO2003081234A3 (en) | Diagnostics and therapeutics for diseases associated with homo sapiens g - protein - coupled receptor 8 (gpr8) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |